Randomized comparison between fluconazole and itraconazole for the treatment of candidemia in a pediatric intensive care unit: A preliminary study

Pediatric Critical Care Medicine

Volumn 5, Issue 6, 2004, Pages 561-565

  Mondal, Rakesh K ^a   Singhi, Sunit C ^a   Chakrabarti, Arunaloke ^a   Jayashree, M ^a  

^a POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

Candidemia; Fluconazole; Itraconazole; Nosocomial infections.

Indexed keywords

ANTIFUNGAL AGENT; FLUCONAZOLE; ITRACONAZOLE;

ARTICLE; CANDIDIASIS; CHILD; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSS INFECTION; DOUBLE BLIND PROCEDURE; FEMALE; FUNGEMIA; HUMAN; INFANT; INTENSIVE CARE; MALE; MORTALITY; PRESCHOOL CHILD; RANDOMIZED CONTROLLED TRIAL;

ANTIFUNGAL AGENTS; CANDIDIASIS; CHILD; CHILD, PRESCHOOL; CROSS INFECTION; DOUBLE-BLIND METHOD; FEMALE; FLUCONAZOLE; FUNGEMIA; HUMANS; INFANT; INTENSIVE CARE UNITS, PEDIATRIC; ITRACONAZOLE; MALE;

EID: 21644460453     PISSN: 15297535     EISSN: 19473893     Source Type: Journal    
DOI: 10.1097/01.PCC.0000144712.29127.81     Document Type: Article

References (25)

1. Pfaller MA, Epidemiology and control of fungal infection. Clin Infect Dis 1994; 19(Suppl): 8-13
2. Jarvis WR, Edwards JR, Culver DH, et al: Nosocomial infection rates in adult and pediatric care units in US. Am J Med 1991; 9(Suppl 3B):86-89
3. Wey S, Motoni M, Pfaller MA, et al: Risk factors for hospital acquired candidemia. A matched case-control study. Arch Intern Med 1989; 149:2349-2353
4. Paganini H, Brieshke TR, Santos P, et al: Risk factors for nosocomial candidemia: A casecontrol study in children. J Hosp Infect 2002; 50:304-308
5. Wey SB, Mori M, Pfaller MA, et al: Hospital acquired candidemia: The attributable mortality and excess length of stay. Arch Intern Med 1988; 148:2642-2645
6. Wainer S, Cooper PA, Gouws H, et al: Prospective study of fluconazole therapy in systemic neonatal fungal infection. Pediatric Infect Dis J 1997; 16:763-767
7. Driessen M, Ellis JB, Cooper PA, et al: Fluconazole vs amphotericin B for treatment of neonatal fungal septicemia: A prospective randomized trial. Pediatr Infect Dis 1996; 15:1107-1112
8. Hiranandani M, Singhi S, Kaur I, et al: Disseminated nosocomial candidiasis in a pediatric intensive care unit. Indian Pediatr 1995; 32:1159-1166
9. Chakrabarti A, Singh K, Narang A, et al: Outbreak of Pichia anomala infection in the pediatric service of a tertiary care center in northern India. J Clin Microbiol 2001; 39: 1702-1706
10. Abi-Said D, Anaissie E, Uzun O, et al: The epidemiology of hematogenous Candidiasis caused by different Candida species. Clin Infect Dis 1997; 24:1122-1128
11. Pfaller MA, Jones RN, Messer SA, et al: National surveillance of blood stream infection due to species of Candida other than C. albicans: Frequency of occurrence and antifungal susceptibility in the SCOPE program. Diagn Microbiol Infect Dis 1998; 30:121-129
12. Singhi S, Reddy TCS, Chakrabarti A. Candidemia in a pediatric intensive care unit. Pediatr Crit Care Med 2004; 5:369-374
13. Bhandari V, Narang A, Kumar B, et al: Itraconazole therapy for disseminated candidiasis in a very low birth weight neonate. J Pediatr Child Health 1992; 28:323-324
14. Singhi SC, Reddy TS, Chakrabarti A: Oral itraconazole therapy in treatment of candidemia in a pediatric intensive care unit. Indian J Pediatr 2004; In Press.
15. Narang A, Agrawal P, Chakrabarti A, et al: Fluconazole in the management of neonatal systemic candidiasis. Indian Pediatr 1996; 33:823-826
16. Driessen M, Ellis JB, Muwazi F, et al: The treatment of systemic candidiasis in neonates with the fluconazole. Annals Trop Paediatr 1997; 17:263-271
17. de Repentigny L, Ratelle J: Comparison of itraconazole and ketoconazole in HIVpositive patients with oropharyngeal or esophageal candidiasis. Chemotherapy (Basel) 1996; 42:374-383
18. Lass-Florl C, Gunsilius E, Gastl G, et al: Fungal colonization in neutropenic patients: A randomized study comparing itraconazole solution and amphotericin B solution. Ann Hematol 2003; 82:565-569
19. Grant MS, Dissold SP: Itraconazole. A review of its pharmacokinetic and pharmacodynamic properties and therapeutic use in superficial and systemic mycosis. Drugs 1989; 37:310-344
20. Lee JW, Seibel NL, Amantea M, et al: Safety and pharmacokinetics of fluconazole in children with neoplastic disease. J Pediatr 1992; 120:987-993
21. Chakrabarti A, Mohan B, Shrivastava SK, et al: Change in distribution and antifungal susceptibility of Candida species isolated from candidemia cases in a tertiary care centre during 1996-2000. Indian J Med Res 2002; 116:5-12
22. Gupta AK, Cooper EA, Ginter G: Efficacy and safety of itraconazole use in children. Dermatol Clin 2003; 21:521-535
23. de Repentigny L, Ratelle J, Leclerc JM, et al: Repeated-dose pharmacokinetics of an oral solution of itraconazole in infants and children. Antimicrob Agents Chemother 1998; 42:404-408
24. Schmitt C, Perel Y, Harousseau JL, et al: Pharmacokinetics of itraconazole oral solution in neutropenic children during longterm prophylaxis. Antimicrob Agents Chemother 2001; 45:1561-1564
25. Goldman M, Cloud GA, Smedema M, et al: Does long-term itraconazole prophylaxis result in in-vitro azole resistance in mucosal Candida albicans isolates from persons with advanced human immunodeficiency virus infection? Antimicrob Agents Chemother 2000; 44:1585-1587